FDA issues rules for investigational drugs
August 17th 2009The U.S. Food and Drug Administration published two rules recently to help clarify how very ill patients can obtain access to investigational drugs and biologics when they are not eligible to participate in a clinical trial and have no other satisfactory treatment options.
NACDS, NCPA forge on with Medicaid lawsuit
August 13th 2009The National Association of Chain Drug Stores and the National Community Pharmacists Association are moving ahead with their lawsuit against Delaware's changes to Medicaid reimbursement rates, even after Walgreen Co. said it no longer supports the suit.
University of Utah breaks ground on new pharmacy college building
August 12th 2009The University of Utah College of Pharmacy, joined by friends, supporters, members of The ALSAM Foundation, and Mr. and Mrs. L.S. Skaggs, broke ground on a $69-million research facility to be known as the L.S. Skaggs Pharmacy Institute.
Pharmacists can help meet Joint Commission standards
August 10th 2009For hospitals and health systems, Joint Commission accreditation is an ongoing issue of vital importance. With their specialized knowledge and skills, pharmacists can contribute greatly to the continuous process of refining goals and meeting standards.
NCPA seeks to correct flex spending requirements
August 5th 2009The National Community Pharmacists Association (NCPA) recently wrote to a key standards-setting body requesting action on a number of regarding a new Internal Revenue Service requirement meant to ensure flexible spending account debit cards are used properly that is seen by the association as problematic.
NCPA continues fight against surety bond
July 29th 2009The National Community Pharmacists Association (NCPA) is still working to urge Congress to exempt community pharmacies from the Oct. 1 accreditation and surety bond requirements needed to continue providing durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) to Medicare patients.
FDA approves new drug indication for Forteo
July 28th 2009On July 23, Eli Lilly and Company announced the Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture.
NCPA announces 2009 competition finalists
July 22nd 2009Earlier this week at the annual meeting of the American Association of Colleges of Pharmacy (AACP) in Boston, Mass., teams of pharmacy students from three universities were named as finalists in the Pruitt-Schutte Student Business Plan Competition sponsored by the National Community Pharmacists Association (NCPA).
AACP session promotes humanity in pharmacy
July 20th 2009Carolyn Brackett, PharmD, Associate Professor of Clinical Pharmacy at Ohio State University?s College of Pharmacy believes it?s possible to bring more humanity and human-to-human interaction to pharmacy ? regardless of the area in which they practice.
AACP teaches graduate students how to market themselves
July 19th 2009As the 2009 American Association of Colleges of Pharmacy (AACP) Annual Meeting started July 18, one of the first issues on the agenda was pharmacists who plan on entering academia and how graduate students can make the transition into a faculty position.
NCPA, NACDS welcome AMP hearing postponement
February 27th 2009The National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) applauded a decision by U.S. District Judge Royce C. Lamberth to postpone a February hearing about Medicaid Average Manufacturer Price (AMP).
UCSF investigators: Drug companies distort trial information
December 17th 2008A team of medical investigators at the University of California, San Francisco, has accused drug companies of bias by distorting the results of their trials in medical journals, which many doctors rely on to determine whether to prescribe new drugs.
FDA recalls unapproved devices
December 16th 2008The U.S. Food and Drug Administration recently recalled two unapproved and uncleared devices whose manufacturers claimed could treat various medical conditions. The recall was a Class 1, which means there is a reasonable probability that the use of a device will cause adverse reactions, including death.